Alan Glicklich
Officer at Chinook Therapeutics, Inc. (KDNY)
Alan Glicklich has filed 9 insider reports with the SEC since February 2021, as director at CalciMedica, Inc. (CALC) and officer at Chinook Therapeutics, Inc. (KDNY). Alan Glicklich made no open-market purchases or sales in the last 12 months. The latest filing, on August 21, 2026, reports grant or award at CalciMedica, Inc. (CALC).
- Filings
- 9
- Companies
- 2
- Bought on market
- None
- Sold on market
- $357K
Companies where Alan Glicklich is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince January 2025 | $1.26 | Aug 21, 2026 | |||||
| Officer | 7,891 | $357K | Feb 15, 2022 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Aug 19, 2026CALCSEC Form 4 filed by Director Glicklich AlanForm 4Grant or award
- Oct 13, 2025CALCSEC Form 4 filed by Director Glicklich AlanForm 4Grant or award
- Jun 24, 2025CALCSEC Form 4 filed by Director Glicklich AlanForm 4Grant or award
- Jan 15, 2025CALCSEC Form 4 filed by Director Glicklich AlanForm 4Grant or award
- Jan 15, 2025CALCAlan Glicklich became an insiderForm 3New insider
- Feb 11, 2022-$30.5KKDNYSEC Form 4: Glicklich Alan sold $30,464 worth of shares (2,391 units at $12.74) and converted options into 5,668 shares, increasing direct ownership by 71% to 7,891 units (withholding obligation)Form 4Exercise or conversion of a derivativeOpen-market sale
- Oct 6, 2021KDNYSEC Form 4: Glicklich Alan converted options into 7,103 shares and covered exercise/tax liability with 2,489 shares to satisfy tax liabilityForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Jun 16, 2021-$327KKDNYSEC Form 4: Glicklich Alan sold $326,968 worth of Common Stock (20,000 units at $16.35) and exercised 20,000 units of Common Stock at a strike of $0.42Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
Also sits on boards with
Officers and directors who share two or more companies with Alan Glicklich.
Compare Alan Glicklich with
- Alan Glicklich vs Eric Bjerkholt2 shared
- Alan Glicklich vs Sean Patrick Lawler1 shared
- Alan Glicklich vs Eric W Roberts1 shared
- Alan Glicklich vs Kenneth A. Stauderman1 shared
- Alan Glicklich vs Sudarshan Hebbar1 shared
- Alan Glicklich vs Stephen Bardin1 shared
Other insiders at the same companies
- Sean Patrick LawlerCALC
- Eric W RobertsCALC
- Kenneth A. StaudermanCALC
- Sudarshan HebbarCALC
- Stephen BardinCALC
- A. Rachel LehenyCALC
- Alafi Capital Co LLCCALC
- Allan ShawCALC
- Frederic GuerardCALC
- Evgeny ZaytsevCALC
- Robert N WilsonCALC
- Fred A MiddletonCALC
- Michael J. DunnCALC
Questions about Alan Glicklich
- What is Alan Glicklich's role at Chinook Therapeutics, Inc.?
- Alan Glicklich reports to the SEC as officer at Chinook Therapeutics, Inc. (KDNY), according to the latest filing on February 15, 2022. Alan Glicklich has also filed as director at CalciMedica, Inc. (CALC).
- How many shares does Alan Glicklich own?
- After the latest filing that states it, Alan Glicklich directly owned 7,891 shares of Chinook Therapeutics, Inc. (KDNY). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Alan Glicklich bought or sold stock recently?
- The most recent open-market sale was on February 11, 2022: sold 2,391 shares of Chinook Therapeutics, Inc. (KDNY) for $30.5K at an average of $12.74.
- How do I get alerts when Alan Glicklich files?
- Follow Alan Glicklich on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Alan Glicklich (SEC CIK 0001823197). Totals count each trade once, skipping amendments whose original is on file, from Feb 12, 2021 on. View on SEC EDGAR · Get this as JSON